Affordably Source Cancer Immunotherapy Experts and Industry Participants for Market Research, Diligence and Projects

Submit an anonymous Project Description -- Start receiving responses within a few hours

Have a need? Explain it here






How Zintro Works

  1. 1. Provide a clear description of your needs and your expectations of an expert, consultant or job candidate and Zintro will match it with the most relevant professionals in our platform.
  2. 2. Within a day or two typically 6 - 12 Experts, who have opted-in, will contact you with a brief explanation of their qualifications and how they can help.
  3. 3. You can communicate back and forth, qualify each other, connect and pay fees to Experts through Zintro.
  4. Zintro is free, anonymous and without obligation.

Loved by Thousands

Loved by thousands logos

Need Help?A phone icon1-877-236-7016

Recent Cancer Immunotherapy Inquiries

Area Icon

Cancer Immunotherapy

Need an expert on cancer immunotherapy drug development with a special focus on biomarkers to discuss biomarker strategy, tactics and operational considerations.This immunotherapy targets t-cell response.

  1. Profile Picture

    Paul |Principal

    Subject area expert. Currently advise multiple clients in the ImmRx space (ADC, alt scaffolds, IO). ...

    1.2 Hours Later
  2. Profile Picture

    Denise |Director, Project Management

    Expert level drug development CRO with extensive biomarker experience in immunotherapy - noblelifesc...

    1.4 Hours Later
  3. Profile Picture

    Martha |Consultant

    I'd love to help. I have 12 years of oncology biomarker experience in clinical trials at Novartis an...

    1.5 Hours Later
+12 Other Responses
Area Icon

Recurrent Astrocytoma Consult

My name is jon and i am writing to you about my uncle, vin, who has been battling brain cancer since 1997. Having recently suffered a third recurrence, he is running out of options that might provide him with the safest, most efficacious option(s) to manage his condition. That said, as he awaits the results from an upcoming mri, we are focused on obtaining opinions from several leading experts in the field regarding the best approach moving forward…which has led me to send you this message. Below you can find a very brief timeline of his history. We would be very interested in any insight you might be able to provide and would agree to any amount of compensation that would be needed for your time in reviewing his case. I would sincerely appreciate if you could let me know if this would or would not be a possibility. If it would be, we could promptly complete the authorization needed to get you his records. Thank you in advance. We look forward to hearing from you. Jon dooley clinical research assistant hospital of the university of pennsylvania vincent patrone board member, national brain tumor society 1997- diagnosed with an oligo-astrosytoma in 1997. Had surgery and chemotherapy (ccnu) 2005- recurrence diagnosed as grade iii anaplastic astrocytoma. Had surgery, radiation, and chemotherapy (alternating temadar and ccnu). 2012- recurrence diagnosed as grade iii anaplastic astrocytoma. Had surgery in first week of january 2012, has been on temadar for 43 days but treatment has temporarily been halted to allow a four week treatment-free period so that he can meet the inclusion/exclusion criteria of a clinical trial. This has been suggested as the route to proceed since his treatment physicians are reluctant to radiate or excise the tumor again. *region: left temporal lobe

  1. Profile Picture

    Craig |Founder of Health Alkemy

    Hi, I can propose to help, giving you diet, and herbal options, along with lifestyle and self-care r...

    3.2 Hours Later
  2. Profile Picture

    Floyd |Chief Pathologist

    While I cannot give specific medical advice long distance I can share *****t a low non to...

    22.6 Hours Later
  3. Profile Picture

    Rivka |Physician

    Hello, I am heavily involved in research in glioblastoma multiforme. I am a neuroradiologist in brai...

    1.1 Days Later
+6 Other Responses
Area Icon

Metastatic Pancreatic Cancer Therapy Market

We are looking for participants who can speak on the market access landscape for current and future metastatic pancreatic cancer therapies in germany. We are interested to speak with the following: - current or former regional / local payer; former national payer / consultant - kol stakeholders: ludwig-maximilians-universitat (lmu) munchen; joint practice for interdisciplinary oncology and hematology, freiburg this is a 60-minutes paid phone interview and a 90-minutes paid phone interview. Please provide a brief answer as to your relevance to this space: for payers: 1. How would you describe your current role? 2. Have you participated in any market research studies in the past month regarding metastatic pancreatic cancer? For kol stakeholders: 1. What is your primary specialty? 2. Approximately how many metastatic pancreatic cancer patients do you consult and/or treat on a monthly basis? 3. Please score your level of expertise and insight on the metastatic pancreatic cancer space from 1 to 5, where 1 is low and 5 is high. Please briefly elaborate. 4. Please score your ability to discuss the impact of clinical evidence packages on regulatory approval, access, and reimbursement in your market from 1 to 5, where 1 is low and 5 is high. Please briefly elaborate. 5. Please score your ability to review product profiles and provide thoughts on data points that would be most relevant to shape decision-making in your market from 1 to 5, where 1 is low and 5 is high. Please briefly elaborate. 6. Have you ever advised national, regional, and/or local healthcare decision-making bodies in your market? Please briefly elaborate.

  1. Profile Picture

    Werner |Head of MSL Oncology

    Rate: $250 1. What is your primary specialty? a. Oncology - Pharmaceutical Industry 2. Approximat...

    18 Hours Later
  2. Profile Picture

    Volker |European Life Science Accelerator/Pharma

    Yes, I am interested. 1. How would you describe your current role? - Consultant Pharma & Biotech 2...

    1.2 Days Later
  3. Profile Picture

    Hartmut |Medical Leader Benefit Assessment Cancer

    1. What is your primary specialty? Ans: Medical Affairs and benefit assessment in the pharmaceutica...

    1.4 Days Later
+14 Other Responses
Area Icon

Advanced Cancer Tests And Treatments As A Concierge Service

Venture capitalist thinking of investing in a company which provides information about advanced cancer tests and treatment and concierge services to consumers; high price/high value fee for service. Looking for experts to help me understand this space.

  1. Profile Picture

    Shiva Murthy |Director, Clinical research and Business

    Hi Thanks for contacting me. I am interested to discuss on this. Let us fix up time mutually conveni...

    1.5 Hours Later
  2. Profile Picture

    Scott |Director of Basic Urologic Research; Ass

    Hi AB, I would be happy to serve as a consultant, however I want to ensure that my area of expert...

    1.6 Hours Later
  3. Profile Picture

    Mark |Management Consultant

    I would like to explore further to see if I might be able to shed light in this space. I have 10 yea...

    1.7 Hours Later
+11 Other Responses
Area Icon

Lung Cancer Drug Market

We are looking to speak to experts about market access and pricing landscape for non-small cell lung carcinoma (nsclc) and the role/perception of immuno-oncology drugs within the landscape (e.G. Keytruda, opdivo, etc.). We are interested to speak to spanish regional pharmacy directors / regional payer. This would be for a 1-hour paid phone consult. Please respond with a few brief statements as to your relevance in this space. 1. Please rank your level of experience and insight on the following products used for nsclc treatment on a scale of 1 to 5 (1 = low, 5 = high). Please briefly elaborate. - opdivo: - keytrude: - tecentriq: - imfinzi: 2. Would you be able to review key value themes and provide thoughts on data points that would be most relevant to shape across decision-making within their market? Please briefly elaborate.

  1. Profile Picture

    Sonia |Medical Director

    Yes, I am interested. I could make myself available next Monday. Regards, Sonia...

    7.9 Hours Later
  2. Profile Picture

    Ignacio |Head of Department of Oncology

    Yes, I’d be interested and available during the next few days. I’m a medical oncologist specialized...

    3.9 Days Later
  3. Profile Picture

    José |Consultant Oncologist

    Yes, I am interested. Please find my answers below:- 1. Please rank your level of experience and i...

    6.1 Days Later
+5 Other Responses
Area Icon

Stereotactic Radiosurgery

I am in need of an expert on stereotactic radiosurgery treatment of brain cancer.

  1. Profile Picture

    Jon |Assistant Professor of Radiation Oncolog

    I am an expert on SRS (stereotactic radiosurgery) for both CNS and extra-cranial *****. I u...

    1.6 Hours Later
  2. Profile Picture

    Maida |Health Care Consultant and Writer

    Hi there, I am an expert on stereotactic radiosurgery-have worked at MGH where this was pioneered, ...

    2.4 Hours Later
  3. Profile Picture

    Victor |Emeritus Professor/Consultant

    I am a neuro-oncologist and use SRS and work with *****logists weekly....

    16.4 Hours Later
+16 Other Responses
Area Icon

Norwegian Market In Bladder Cancer

We are looking for participants who can speak on the market access landscape for bladder cancer therapies in norway. We are interested to speak with the following: - heor expert payers - healthcare providers (hematologists/oncologists/urologists) this is a 60-minutes paid phone interview. Please provide a brief answer as to your relevance to this space: for heor expert payers: 1. Please rate your level of expertise on the following topics on a scale of 1-5, where 1 represents low expertise and 5 represents industry-leading expertise: - national, regional or local hta assessments - risk-benefit and heor calculations - economic modeling & clinical trial review - pricing and reimbursement of adjuvant treatments in oncology 2. Have you ever advised national, regional, and/or local healthcare decision-making bodies in your market? Please briefly elaborate for healthcare providers: 1. Please rate your level of expertise on the following topics on a scale of 1-5, where 1 represents low expertise and 5 represents industry-leading expertise: - national, regional or local hta assessments - clinical trial design and clinical endpoint evaluation - patient sub-group analysis and patient population definition - muscle-invasive bladder cancer therapy selection - adjuvant therapy selection 2. Have you ever directly advised national, regional, and/or local healthcare decision-making bodies in your market? Please briefly elaborate.

  1. Profile Picture

    Eivid |Managing Director

    Rate: $250 Yes, I can help. I have been working with HE&MA for 20 years. I quite frequently have su...

    5.6 Hours Later
  2. Profile Picture

    Jan |Oncologist, Researcher

    rate: $250 Oslo Area, Norway I might be interested. FOR HEALTHCARE PROVIDERS: Have experience all...

    17.6 Hours Later
  3. Profile Picture

    Markus |First line sales manager

    Sorry, i have only knowledge of the german pharma / healthcare market...

    7.4 Days Later
+7 Other Responses
Area Icon

Cancer Vaccine

I am looking for a nj or ny-based consultant who is an expert in running clinical trials for cancer vaccines

  1. Profile Picture

    Lokesh |Program Director

    I am an Independent consultant who has consulted with Company's like Astrazeneca, MedImmune and Sano...

    1.4 Hours Later
  2. Profile Picture

    Remco |Director of Biology

    I have experience with experimental preclinical cancer vaccines (immunotherapy) but not clinical tri...

    3 Hours Later
  3. Profile Picture

    Tony |President

    I am have not run any oncology vaccine trials, however, I have performed in-depth analyses of data f...

    8 Days Later
+4 Other Responses
Area Icon

Secondary-immunodeficiency In Blood Cancer

We would like to speak with physicians ( hematologist-oncologists, immunologists, and infectious disease specialists) involved in the diagnosis, treatment, and ongoing management of patients with sid that is associated with chronic lymphocytic leukemia (cll), multiple myeloma (mm), or non-hodgkin’s lymphoma (nhl). We are aiming to carry out message testing to identify messages that are most compelling to physicians with respect to the diagnosis and treatment of secondary immune deficiency (sid) associated with hematological cancers. This is a 75-minutes paid phone consultation and a 10 minutes pre-task. If open to participating, please provide a brief answer to the screener below: 1. Do you see at least 10 patients per month with secondary immunodeficiency (sid) associated with chronic lymphocytic leukemia (cll), multiple myeloma, or non-hodgkin’s lymphoma (nhl)? Please note that we are only interested in your personal point of view and are not seeking confidential information. Referrals are highly appreciated

  1. Profile Picture

    Mart |Marketing Director SPECT Europe

    Sorry no real *****, I'm not a physician and not in any way involved in ***** CLL. There...

    16 Hours Later
  2. Profile Picture

    VICTOR |Zintro Expert

    Thanks for asking for insights on this subject ***** confirm my availability for this consult...

    16.5 Hours Later
  3. Profile Picture

    Alessandro |Healthcare Manager

    I am not a physician but I have experience as biologist/***** payer....

    17.1 Hours Later
+6 Other Responses
Area Icon

Cancer Cell Biology

Mitoxantrone resistant cancer cells from any organism, preferably human, mouse, or rat

  1. Profile Picture

    Sonia |Senior Postdoctoral Associate

    Hello, I am an expert in cancer biology, cell biology as well as tumor immunology.I would like very...

    7.2 Hours Later
  2. Profile Picture

    Angel |Director of biobank, Group Leader

    My company is focused on providing high quality research services in the functional testing of anti-...

    18.7 Hours Later
+2 Other Responses
Area Icon

Breast Cancer

The zintro blog needs you!i’m looking for your expert opinion on the news below and a written response that is one to three paragraphs long.Your response may be used in an article that i will write and post on the zintro site.You will be named in the article and a link to your profile will be included.Your contribution is voluntary(there is no direct payment involved,but you will get lots of traffic to your profile).If interested,please send me your response via znotes within the next few days. Uc irvine medical center is the first in usa to use the marginprobe system,which reduces by half the need to reoperate and cut out breast cancer cells missed during an initial lumpectomy.When the probe touches an excised lumpectomy specimen,radio-frequency signals are transmitted into the tissue and reflected back to the console,where they’re analyzed using a specialized algorithm to determine tissue status.Will this method reduce the need for repeat surgeries? This is a great marketing opportunity to get your name and opinion published on our blog.Here is a sample: http://blog.Zintro.Com/2012/01/16/keystone-xl-pipeline-pros-and-cons/ please include your full name,we will link it to your expert profile,getting you more presence on zintro.If you have any questions,please let me know. Thank you! idil kan

  1. Profile Picture

    Vaidyaraj |director

    How disease occurs according to ayurveda? The small illness like cold, cough, fever, pain, headache...

    2.7 Hours Later
  2. Profile Picture

    Rita |Principle

    When do you need this by? I am not able to provide until June 14th. Best regards, Rita...

    2.1 Days Later
+2 Other Responses
Area Icon

Genetic Cancer Screening

We are a prominent research firm and an authorized zintro partner. Our client has an immediate need to conduct phone consults with multiple experts knowledgeable about reimbursement for genetic cancer screening tests esp brca to understand the overall market. Ideal candidates would be individuals who have direct experience in evaluating such services for reimbursements for a mid to large sized health insurer.

  1. Profile Picture

    Sherry |Dental Hygienist

    Oral cancer screening...

    1.4 Hours Later
  2. Profile Picture

    Brad |Consultant

    I have 15 years of experience working in the genetic cancer screening tests, esp BRCA reimbursement,...

    2.2 Hours Later
  3. Profile Picture

    James |Co-founder, & VP Marketing

    There have some changes the coding system concerning the cancer genetic marker, causing the *****...

    2.7 Hours Later
+6 Other Responses
See More Inquiries

use of the immune system to reject cancer. The main premise is stimulating the patient`s immune system to attack the malignant tumor cells that are responsible for the disease

Top Cancer Immunotherapy Experts

See More Experts
Share
LinkedInTwitterFacebookGoogle+